Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 9/20 | 0.67 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | P2RX7 | Q99572 | 5/20 | 0.46 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.42 |
| ▸ | USP19 | O94966 | 1/20 | 0.40 |
| ▸ | ABHD6 | Q9BV23 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17881978 | 0.85 | RIPK1 (0.62) | RIPK1ABHD6 | |
| SCHEMBL28167616 | 0.84 | RIPK1 (0.66) | RIPK1POLBMEN1TSHRHTT | |
| SCHEMBL17881890 | 0.83 | RIPK1 (0.76) | RIPK1MEN1TSHRHTTKMT2A | |
| SCHEMBL17881976 | 0.81 | RIPK1 (1.00) | RIPK1 | |
| SCHEMBL17881984 | 0.81 | RIPK1 (1.00) | RIPK1 | |
| SCHEMBL17881895 | 0.79 | RIPK1 (0.84) | RIPK1 | |
| SCHEMBL17881977 | 0.79 | RIPK1 (0.84) | RIPK1 | |
| SCHEMBL17881971 | 0.77 | RIPK1 (0.82) | RIPK1 | |
| SCHEMBL28848822 | 0.77 | RIPK1 (0.64) | RIPK1P2RX7 | |
| SCHEMBL28536599 | 0.76 | RIPK1 (0.80) | RIPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11478438-B2 | Necrosis inhibitors | NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) | 2022-10-25 | — | — | US | disclosed |
| US-11090307-B2 | Treating male senescence | NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) | 2021-08-17 | — | — | US | disclosed |
| CN-107108492-B | Cell necrosis inhibitor | 北京生命科学研究所 | 2021-03-19 | — | — | CN | disclosed |
| US-20200182617-A1 | Necrosis Inhibitors | NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) | 2020-06-11 | — | — | US | disclosed |
| US-20200182617-A1 | Necrosis Inhibitors | NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) | 2020-06-11 | — | — | US | disclosed |
| US-20200046714-A1 | Treating Male Senescence | NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) | 2020-02-13 | — | — | US | disclosed |
| US-10555920-B2 | Necrosis inhibitors | NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) | 2020-02-11 | — | — | US | disclosed |
| US-10555920-B2 | Necrosis inhibitors | NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) | 2020-02-11 | — | — | US | disclosed |
| US-20190038578-A1 | Necrosis Inhibitors | NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) | 2019-02-07 | — | — | US | disclosed |
| US-20190038578-A1 | Necrosis Inhibitors | NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) | 2019-02-07 | — | — | US | disclosed |
| US-10092529-B2 | Necrosis inhibitors | NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) | 2018-10-09 | — | — | US | disclosed |
| EP-3224245-B1 | NECROSIS INHIBITORS | NAT INSTITUTE OF BIOLOGICAL SCIENCES BEIJING (CN) | 2018-09-12 | — | — | EP | disclosed |
| US-20170304237-A1 | Necrosis Inhibitors | NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) | 2017-10-26 | — | — | US | disclosed |
| US-20170304237-A1 | Necrosis Inhibitors | NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) | 2017-10-26 | — | — | US | disclosed |
| US-20170304237-A1 | Necrosis Inhibitors | NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) | 2017-10-26 | — | — | US | disclosed |
| WO-2016101887-A1 | NECROSIS INHIBITORS | NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) | 2016-06-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170304237-A1 | Necrosis Inhibitors | RIPK3, RIPK1, RIPK4 | RIPK1 2/4885POLB 4370/4885MEN1 3275/4885 |
| US-11478438-B2 | Necrosis inhibitors | RIPK3, RIPK1, RIPK4 | RIPK1 2/4885POLB 4368/4885MEN1 3176/4885 |
| US-11090307-B2 | Treating male senescence | RIPK3, RIPK1, MLKL | RIPK1 2/4885POLB 3114/4885MEN1 1003/4885 |
| US-20200046714-A1 | Treating Male Senescence | RIPK3, RIPK1, MLKL | RIPK1 2/4885POLB 3114/4885MEN1 1003/4885 |
| US-20190038578-A1 | Necrosis Inhibitors | RIPK3, RIPK1, RIPK4 | RIPK1 2/4885POLB 4368/4885MEN1 3176/4885 |
| US-10092529-B2 | Necrosis inhibitors | RIPK3, RIPK1, RIPK4 | RIPK1 2/4885POLB 4370/4885MEN1 3275/4885 |
| US-10555920-B2 | Necrosis inhibitors | RIPK3, RIPK1, RIPK4 | RIPK1 2/4885POLB 4368/4885MEN1 3176/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.